NGEN
NASDAQ · Pharmaceuticals
Nervgen Pharma Corp
$1.62
+0.02 (+1.25%)
Open$1.66
Previous Close$1.60
Day High$1.66
Day Low$1.59
52W High$8.49
52W Low$2.71
Volume—
Avg Volume50.7K
Market Cap241.14M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+671.0% upside
Current
$1.62
$1.62
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,185.71 | -0.52% | 41.4 | 1.11T |
| JNJ | Johnson & Johnson | $259.24 | +0.88% | 29.3 | 617.08B |
| MRK | Merck & Co. Inc. | $128.58 | +0.16% | 99.4 | 315.27B |
| PFE | Pfizer Inc. | $26.76 | +2.14% | 34.8 | 150.87B |
| BMY | Bristol-Myers Squibb Co | $64.72 | +0.89% | 14.1 | 131.10B |
| ZTS | Zoetis Inc | $72.66 | -5.97% | 12.3 | 32.39B |